We have located links that may give you full text access.
Impaired lymphocyte transformation in minimal change nephropathy in remission.
Clinical Nephrology 1982 July
A group of 37 patients with minimal change nephropathy (MCN) in remission for a mean period of 4.9 years (range 0.25-10) and on no current treatment were found to have a lymphocyte response to the mitogen Concanavalin A which was significantly lower than normal (P less than 0.001). This reduction in lymphocyte transformation was mainly due to the 24 patients who had received in addition to steroids a course of cyclophosphamide from 1 to 12 years (mean 6.7 years) previously (P less than 0.005 when compared t normal). Although the lymphocyte response of the remaining group of 13 patients who had not been treated with cyclophosphamide was not significantly lower than normal, there were three whose lymphocyte response to Concanavalin A was below the normal range. Our findings indicate that remission of MCN may be accompanied by a persistence of the abnormal lymphocyte function which is present during the nephrotic phase, and that cyclophosphamide may cause or add to this defect by a long-term effect on lymphocytes.
Full text links
Trending Papers
Cardiovascular Disease in Diabetes and Chronic Kidney Disease.Journal of Clinical Medicine 2023 November 9
Monitoring Macro- and Microcirculation in the Critically Ill: A Narrative Review.Avicenna Journal of Medicine 2023 July
Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium-Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction.Diabetes Care 2023 November 22
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app